Search

Displaying results 5801 - 5810 of 10000 in total
  1. Drug

    SGN-15

    go.drugbank.com/drugs/DB05818
    Investigational

    Doxorubicin is a type of anthracycline antitumor antibiotic. When it is combined with a monoclonal antibody, it forms a type of drug conjugate. Also called cBR96-doxorubicin immunoconjugate. … It combines a monoclonal antibody with the anticancer drug doxorubicin. Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells.

  2. Drug

    Roxarsone

    go.drugbank.com/drugs/DB11458
    ExperimentalVet approved

    Roxarsone is an organoarsenic molecule added to poultry feed.

  3. Drug

    5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole

    go.drugbank.com/drugs/DB08724
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. This medication is known to target genome polyprotein. … 5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers.

  4. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.

  5. Drug

    Saposin C

    go.drugbank.com/drugs/DB17380
    Investigational

    Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. … BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.

  6. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).

  7. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

  8. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.

  9. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent. … It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.

  10. Drug

    Ertiprotafib

    go.drugbank.com/drugs/DB06521
    Experimental

    In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test. … Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes.